logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Cystinuria

    Medications for Cystinuria

    FiltersReset Filters
    6 results

    • cuprimine

      (penicillamine)
      Bausch Health US, LLC
      Usage: CUPRIMINE is indicated for treating Wilson's disease, cystinuria, and severe, active rheumatoid arthritis in patients unresponsive to conventional therapy. It is not effective for ankylosing spondylitis. Treatment aims to reduce copper accumulation in Wilson's disease and urinary cystine levels in cystinuria.

    • depen

      (Penicillamine)
      Meda Pharmaceuticals Inc.
      Usage: DEPEN is indicated for treating Wilson’s disease, cystinuria, and severe rheumatoid arthritis in patients who have not responded to conventional therapy. It helps minimize copper intake and promotes copper excretion in Wilson’s disease, reduces cystine excretion to prevent stone formation in cystinuria, and assists in managing severe rheumatoid arthritis.

    • penicillamine

      (penicillamine)
      Par Pharmaceutical, Inc.
      Usage: Penicillamine tablets are indicated for treating Wilson’s disease, cystinuria, and severe rheumatoid arthritis that has not responded to conventional therapies. They aid in reducing copper accumulation in Wilson’s disease and managing cystine excretion in cystinuria, while use in rheumatoid arthritis is limited due to potential severe adverse reactions.

    • tiopronin

      (tiopronin)
      Amneal Pharmaceuticals NY LLC
      Usage: Tiopronin delayed-release tablets are indicated, along with high fluid intake, alkali, and dietary changes, for preventing cystine stone formation in adults and children aged 9 and older with severe homozygous cystinuria who do not respond to standard treatments.

    • tiopronin

      (Tiopronin)
      Biocon Pharma Inc.
      Usage: Tiopronin Delayed-Release Tablets are indicated for preventing cystine stone formation in adults and pediatric patients (≥20 kg) with severe homozygous cystinuria, when combined with high fluid intake, alkali, and dietary modifications.

    • venxxiva

      (tiopronin)
      Cycle Pharmaceuticals Ltd.
      Usage: VENXXIVA is indicated for the prevention of cystine stone formation in adults and pediatric patients aged 9 and older with severe homozygous cystinuria, in combination with high fluid intake, alkali, and dietary modifications, for those not responsive to other measures.